Early proof-of-concept
Early preclinical proof-of-concept work with a clear development plan towards clinical testing.
Investments
Bridging the early-stage funding gap in autoimmune research.
IBC fuels breakthroughs in autoimmune therapeutics, diagnostics, and enabling technology — speeding the path from discovery to life-changing cures.
Our Investment Approach
Catalytic capital, deployed where the science needs it most.
Progress in autoimmune research requires access to risk-tolerant early capital — a resource that is increasingly scarce. IBC partners with founders to generate decisive data, unlock follow-on funding, and accelerate therapies and diagnostics into commercial development.
- Initial and co-investments up to $500K
- Pre-clinical to IND-enabling stage
- Diagnostics at analytical or clinical validation
- Therapeutics, diagnostics, and enabling tech
- Syndication-friendly with VCs and strategics
- Clear milestones to Seed or Series A readiness
Funding Parameters
What we look for in early-stage opportunities.
Validated signal
Sufficient preliminary data indicating therapeutic and commercial viability for the disease area.
Milestone-driven tranches
Capital deployed in tranches tied to measurable, de-risking events that unlock follow-on funding.
Check Sizes
Right-sized capital, syndication-friendly.
Exploratory seed
$100K – $250K
Earliest catalytic capital to validate hypotheses and generate decisive data.
Initial investment
Up to $500K
Lead or co-invest with flexibility to syndicate alongside aligned VCs and strategics.
Selective follow-on
Catalytic top-ups
Reserved capital to bridge teams to a traditional Seed or Series A round.
Evergreen Model
Every dollar returns to the mission.
- 100% of returns recycled to advance IBC's mission.
- No carry, no management fee — every dollar goes back to research.
- Aligned with founders, patients, and the broader scientific community.
Founder & Investigator Inquiries
Building something that moves autoimmune care forward?
We welcome outreach from emerging companies as well as academic spinouts. Share your team, the science, and the milestones you're chasing — we'll get back to you.
